BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 9179692)

  • 1. PCNA and p53 in urinary bladder cancer: correlation with histological findings and prognosis.
    Inagaki T; Ebisuno S; Uekado Y; Hirano A; Hiroi A; Shinka T; Ohkawa T
    Int J Urol; 1997 Mar; 4(2):172-7. PubMed ID: 9179692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder.
    Shiina H; Igawa M; Nagami H; Yagi H; Urakami S; Yoneda T; Shirakawa H; Ishibe T; Kawanishi M
    Cancer; 1996 Oct; 78(8):1762-74. PubMed ID: 8859190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferating cell nuclear antigen cyclin in human transitional cell carcinoma.
    Hattori K; Uchida K; Akaza H; Koiso K; Nemoto R; Harada M
    Br J Urol; 1995 Feb; 75(2):162-6. PubMed ID: 7850319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage.
    Skopelitou A; Hadjiyannakis M; Dimopoulos D; Kamina S; Krikoni O; Alexopoulou V; Rigas C; Agnantis NJ
    Eur Urol; 1997; 31(4):464-71. PubMed ID: 9187909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of nuclear morphometry and immunostaining for p53 and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder.
    Ogura K; Fukuzawa S; Habuchi T; Ogawa O; Yoshida O
    Int J Urol; 1997 Nov; 4(6):561-6. PubMed ID: 9477184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity.
    Ogura K; Habuchi T; Yamada H; Ogawa O; Yoshida O
    Int J Urol; 1995 Nov; 2(5):302-8. PubMed ID: 8749948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and prognostic value of proliferating cell nuclear antigen in transitional cell carcinoma of the urinary bladder.
    Chen G; Lin MS; Li RC
    Urol Res; 1997; 25(1):25-30. PubMed ID: 9079742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of immunohistochemical markers (PCNA, Ki-67, 486p and p53) on paraffin sections and their relation to the recurrence rate of superficial bladder tumors.
    Vorreuther R; Hake R; Borchmann P; Lukowsky S; Thiele J; Engelmann U
    Urol Int; 1997; 59(2):88-94. PubMed ID: 9392055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Value of the proliferation status (PCNA) and p53 immunohistochemistry as a prognostic factor for the clinical course of superficial cancer of the urinary bladder].
    Kuczyk MA; Serth J; Bokemeyer C; Hervatin C; Oelke M; Oelert F; Höfner K; Jonas U
    Urologe A; 1995 Mar; 34(2):146-52. PubMed ID: 7754587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder.
    Shiina H; Igawa M; Urakami S; Honda S; Shirakawa H; Ishibe T
    J Clin Pathol; 1996 May; 49(5):395-9. PubMed ID: 8707954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 immunoreactivity in biopsy specimens of T1G3 transitional cell carcinoma of the bladder--a helpful parameter in guiding the decision for or against cystectomy?
    Steiner G; Bierhoff E; Schmidt D; Leissner J; Wolf HK; Albers P
    Eur J Cancer; 2000 Mar; 36(5):610-4. PubMed ID: 10738125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical studies of proliferating cell nuclear antigen and cathepsin D in transitional cell carcinoma of the urinary bladder.
    Iizumi T; Iiyama T; Tanaka W; Okada E; Kamiyama Y; Okano Y; Sato S; Yazaki T; Umeda T; Imamura T
    Urol Int; 1997; 59(2):81-7. PubMed ID: 9392054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical evaluation of p53, proliferating cell nuclear antigen (PCNA) and bcl-2 expression during bacillus Calmette-Guerin (BCG) intravesical instillation therapy for superficial bladder cancers.
    Okamura T; Akita H; Kawai N; Tozawa K; Yamada Y; Kohri K
    Urol Res; 1998; 26(3):161-4. PubMed ID: 9694596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of P21, p53 and proliferating cell nuclear antigen in human bladder cancer].
    Ding Q; Zhang Y; Sun X
    Zhonghua Bing Li Xue Za Zhi; 1997 Aug; 26(4):211-3. PubMed ID: 10072865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement.
    Frank I; Cheville JC; Blute ML; Lohse CM; Karnes RJ; Weaver AL; Sebo TJ; Nehra A; Zincke H
    Cancer; 2004 Oct; 101(8):1803-8. PubMed ID: 15386300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of proliferating cell nuclear antigen expression in transitional cell carcinoma of the upper urinary tract.
    Cheng HL; Chow NH; Tzai TS; Tong YC; Lin JS; Chan SH; Yang WH; Chang CC; Lin YM
    Anticancer Res; 1997; 17(4A):2789-93. PubMed ID: 9252716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
    Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens.
    Tsuji M; Kojima K; Murakami Y; Kanayama H; Kagawa S
    Br J Urol; 1997 Mar; 79(3):367-72. PubMed ID: 9117215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.